Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed

Status Completed

Clinical Trial Summary

The optimal sequence and /or modality for adjuvant therapy in the management of Mixed Mesodermal Tumors (MMT) clearly remains to be established. The rationale for the protocol is to "sandwich" pelvic radiation with chemotherapy to decrease distant metastasis.

The proposed study will sandwich radiation between the two most active chemotherapeutic agents for MMT identified to date (ifosfamide/cisplatin). By doing so, we attempt to decrease both local and distant recurrence, which may translate into an improved progression free interval and possibly even extend survival.

Clinical Trial Description

Uterine sarcomas account for only 2-4% of uterine malignancies, yet they are responsible for 26% of uterine cancer deaths. Mixed mesodermal tumors (MMT), previously known as carcinosarcoma, are the most common of the uterine sarcomas in the United States. Prognosis for these patients is generally grim due to the propensity for early metastatic disease. Patterns of spread are by both hematogenous and lymphatic dissemination. It has been noted that 66% of patients with disease clinically confined to the uterus have nodal metastasis at the time of diagnosis. The majority of patients will die with both wide spread intra-abdominal and pelvic disease within two years of diagnosis.

Adjuvant pelvic radiation therapy has been advantageous in controlling local recurrence. One study reports 26% local recurrence in patients treated with surgery alone versus 14% recurrence in patients treated with surgery and adjuvant pelvic radiation. Although adjuvant radiation shows a benefit in improving local control, it has not been found to impact survival. This finding is likely attributed to the high incidence of distant metastasis (85%) known to occur with disease recurrence.

Multiple chemotherapeutic agents have been evaluated in the management of advanced, persistent or recurrent uterine MMT. Response to single agent therapy has been less than 35% with the most active agents identified being ifosfamide (response rate = 34.8%) and cisplatin (response rate 17.9%. The use of chemotherapy in the adjuvant setting has been explored as a means of attempting to impact the incidence of distant metastasis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00231842
Study type	Interventional
Source	Montefiore Medical Center
Contact
Status	Completed
Phase	Phase 2
Start date	February 2003
Completion date	July 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03285802` - Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation	Phase 2/Phase 3
Completed	`NCT01870947` - Assisted Exercise in Obese Endometrial Cancer Patients	N/A
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Not yet recruiting	`NCT06369155` - Azenosertib in Uterine Serous Carcinoma: Biomarker Study	Phase 2
Not yet recruiting	`NCT05998811` - Insights Into Participating in Studies for Uterine Cancer
Completed	`NCT01399658` - Image-Guided Gynecologic Brachytherapy	Phase 2
Completed	`NCT01432015` - Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting	Phase 4
Recruiting	`NCT02349958` - Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy	Phase 2
Completed	`NCT00581646` - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance	N/A
Completed	`NCT00284427` - Safety of Antioxidants During GYN Cancer Care	Phase 2
Completed	`NCT00147680` - Uterine Papillary Serous Cancer (UPSC) Trial	Phase 2
Recruiting	`NCT05743517` - Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)	N/A
Recruiting	`NCT05916196` - [18F]FES PET/.CT in Uterine Cancer	Phase 2
Withdrawn	`NCT04368130` - SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care	N/A
Active, not recruiting	`NCT03668340` - AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Phase 2
Completed	`NCT00588640` - Study of D-Methadone in Patients With Chronic Pain	Phase 1/Phase 2
Recruiting	`NCT05990426` - Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy	N/A
Completed	`NCT03701529` - Effect of Anesthetic Agents on Optic Nerve Sheath Diameter	N/A
Recruiting	`NCT05758688` - Whole Pelvis Proton Radiation for Gynecologic Cancer	N/A
Completed	`NCT01953107` - Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms